HiRO - Harvest Integrated Research Organization

HiRO is thrilled to announce our strategic partnership with CHA University Bundang Medical Center (CBMC), one of South Korea's leading medical institutions. Together, we have signed an MOU to collaborate on advancing global clinical research. This partnership combines CBMC’s cutting-edge facilities and research expertise with HiRO’s global reach and experience. By joining forces, we aim to make clinical trials more efficient and impactful, helping biotech and pharmaceutical companies deliver innovative treatments to patients faster. As Dr. Karen Chu, HiRO's Founder and CEO, stated, "South Korea is a prime destination for clinical trials, and we are confident that this partnership will further enhance our ability to provide capital-efficient and high-quality clinical trial solutions, leading to impactful results and significant advancements in medical breakthroughs." Dr. Young-Sang Kim, Director of the CHA Global Clinical Trials Center, added, "By leveraging HiRO's presence across the US, Europe, and the Asia-Pacific region, we are strengthening our commitment to delivering more effective and pioneering treatments on a global scale, ultimately improving outcomes for patients in need." Here’s to an exciting journey ahead as we push boundaries and create meaningful change in healthcare! 🌏✨ Learn more about our partnership here: https://lnkd.in/g56fQtDE (English) https://lnkd.in/g-5FdnSU (Korean) https://lnkd.in/ggbPsWPA (Traditional Chinese) https://lnkd.in/gkF9gs5N (Simplified Chinese) #HiRO #CBMC #CHABundangMedicalCenter #CHABioGroup #StrategicPartnership

Having gathered key expert insights, we’ve put together a comprehensive guide of US FDA special designations, providing insights into the various pathways that can potentially transform the drug development process and ultimately improve patient care. #FDASpecialDesignations #DrugDevelopment #PharmaceuticalResearch #RegulatoryPathways #HealthcareInnovation #ExpertInsights

RWE sourced from electronic medical records (EMRs), administrative claims data, disease registries, and various health data repositories can significantly enhances market insights and product positioning strategies. As the demand for real-world-based evidence rises, the integration of RWE becomes increasingly key for every stage of drug development. #RealWorldEvidence #EMRData #DrugDevelopment #MarketInsights #ProductPositioning #HealthData

Japan represents the third-largest drug market as a single country, following only the US and China. As a result, Japan has seen a substantial surge in multi-regional clinical trials (MRCTs) over the past decade. The percentage of global studies in Japan has risen from about 20% to approximately 60%, indicating a growing integration with international drug development efforts and positioning the country as a major contributor to worldwide clinical research. Learn more about maximizing global study value in Japan - https://lnkd.in/g3SCRi7H #JapanDrugMarket #GlobalStudies #MultiRegionalClinicalTrials #InternationalDrugDevelopment

With continued support and policies from the Hong Kong government, the city is increasingly emerging as a favorable location for clinical trials. Hong Kong’s population consist of approximately 7.5 million people as of 2024, offering a substantial and diverse patient pool for medical research. Learn more about running clinical trials in Hong Kong: https://lnkd.in/ghSzq6kv #ClinicalTrials #HongKongResearch #PatientDiversity #MedicalResearch #ResearchOpportunities

Day 1 at ASH was incredible, and we were excited to connect with so many of you! If you haven’t had a chance to stop by yet, there’s still time—visit our team Sheri Smith, Alex Baldridge, CCRA and Carlyle at Booth #1548 to learn how HiRO can support your hematology clinical trials. With a global footprint spanning the US, Europe, and Asia-Pacific, we deliver comprehensive solutions from pre-IND to post-market. Let’s work together to advance innovation and make a meaningful impact in hematology. We look forward to seeing you! 👋 #ASH24 #ASH2024 #Hematology #Oncology #ClinicalTrials #HiRO

We’re ready for ASH 2024! ✨ The ASH Annual Conference kicks off in San Diego from December 7-10, and we can’t wait to connect with you! Visit us at Booth #1548 to meet our amazing US team: Sheri Smith, Alex Baldridge, CCRA, and Carlyle. Learn about our expertise in advancing clinical studies across a range of hematologic malignancies, including AML, ALL, CLL, MDS, MF, lymphoma, multiple myeloma, and more. Let’s explore opportunities to collaborate and make strides in hematology. See you there! 📅 December 7-10 | San Diego Convention Center 👉 See you at Booth #1548 📢 More about ASH 2024: https://lnkd.in/dYZtUjZ #ASH24 #ASH2024 #Hematology #ClinicalResearch #HiRO

🌟 Exciting moments at the MFDS/KSCD Annual Conference! 🌟 This week, we had the privilege of participating in the MFDS/KSCD Annual Conference in Seoul for the first time. We were also honored to host a healthcare investment panel featuring VCs VMS Group, FC CAPITAL, and Korean biotech leaders from SPARK Biopharma, Inc. and YOUTH BIO GLOBAL. The discussion centered on the unique challenges and opportunities biotech companies face today. At HiRO, we’re committed to not only accelerating clinical research but also connecting biotechs with global funding resources, as we truly understand the hurdles they encounter. We hope the insights shared during the panel were valuable to all attendees. We’re grateful for the opportunity and excited to continue our collaboration with KSCD to drive innovation in the industry. A heartfelt thank you to everyone who helped make this experience impactful. Here’s to forging stronger partnerships ahead! 🤝 Karen Chu Dr Cristina K Chang Ya-Han Chang JiHee Noh Junghoon(Gerard) Kim YooJung Hwang #HiRO #KSCD #MFDS #MFDSKSCDConference #BiotechFuture #HealthcareInvestment

🌟 We’re excited to be at the MFDS/KSCD Annual Conference today! Have you visited our booth yet? Come find us and let’s connect! 💬 This afternoon, we’re hosting an engaging panel discussion: "Healthcare Investment Insights: Korean Biotechs in Dialogue with VCs." Join us alongside experts from SPARK Biopharma, Inc., YOUTH BIO GLOBAL, and leading VCs VMS Group and FC CAPITAL as we explore: ● Korea’s healthcare investment landscape ● The global positioning of Korean biotechs ● Fundraising strategies for biotech companies Don’t miss this opportunity for valuable insights and engaging dialogue. See you there! #MFDSKSCDConference #HealthcareInvestment #BiotechFuture #BiotechFundraising #HiRO

With a population of around 23 million, Taiwan presents a large patient pool, with high levels of trust in the local healthcare system. In addition to this, Taiwan's clinical trial industry growth is supported by a regulatory environment that actively facilitates efficient clinical trial execution, offering streamlined processes that enable quick study startups and smooth trial operations. Keep reading to explore key insights into Taiwan's role in global clinical trial development: https://lnkd.in/ghSzq6kv #ClinicalTrials #RegulatoryEnvironment #StudyStartups #HiRO #Taiwan